Magdalena Zalacain

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function
    Magdalena Zalacain
    Microbial, Musculoskeletal and Proliferative Diseases CEDD, Collegeville, PA 17426, USA
    J Mol Microbiol Biotechnol 6:109-26. 2003
  2. ncbi request reprint Peptide deformylase inhibitors
    Kelly Aubart
    Microbial, Musculoskeletal, and Proliferative Diseases CEDD, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, USA
    Prog Med Chem 44:109-43. 2006
  3. pmc Phylogenomic and biochemical characterization of three Legionella pneumophila polypeptide deformylases
    Jianzhong Huang
    Microbiology Department, GlaxoSmithKline, 1250 S Collegeville Road, Collegeville, PA 19426, USA
    J Bacteriol 188:5249-57. 2006
  4. pmc Selection of retapamulin, a novel pleuromutilin for topical use
    Stephen Rittenhouse
    Department of Microbiology Research, MMPD CEDD, GlaxoSmithKline Pharmaceuticals, 1250 S Collegeville Rd, Collegeville, PA 19426 0989, USA
    Antimicrob Agents Chemother 50:3882-5. 2006
  5. pmc Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322
    Karen O'Dwyer
    Antibacterial Discovery Performance Unit, Infectious Disease Therapeutic Area, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Antimicrob Agents Chemother 57:2333-42. 2013
  6. pmc Staphylococcus aureus formyl-methionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity
    Thomas Lewandowski
    Antibacterial Discovery Performance Unit, Infectious Diseases Therapeutic Area, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Antimicrob Agents Chemother 57:2929-36. 2013
  7. pmc Characterization of Streptococcus pneumoniae TrmD, a tRNA methyltransferase essential for growth
    Karen O'Dwyer
    Microbial, Musculoskeletal and Proliferative Diseases CEDD, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    J Bacteriol 186:2346-54. 2004
  8. pmc Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae
    Pan F Chan
    Microbial, Musculoskeletal and Proliferative Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, USA
    J Bacteriol 185:2051-8. 2003
  9. ncbi request reprint Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin
    Glenn S Van Aller
    Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA
    Biochemistry 44:253-60. 2005
  10. doi request reprint Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitors
    Rachel Totoritis
    Department of Biological Reagents, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA
    Biochemistry 50:6642-54. 2011

Collaborators

Detail Information

Publications15

  1. ncbi request reprint A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function
    Magdalena Zalacain
    Microbial, Musculoskeletal and Proliferative Diseases CEDD, Collegeville, PA 17426, USA
    J Mol Microbiol Biotechnol 6:109-26. 2003
    ..Moreover, this study demonstrates that different experimental procedures can produce apparently contradictory results...
  2. ncbi request reprint Peptide deformylase inhibitors
    Kelly Aubart
    Microbial, Musculoskeletal, and Proliferative Diseases CEDD, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, USA
    Prog Med Chem 44:109-43. 2006
  3. pmc Phylogenomic and biochemical characterization of three Legionella pneumophila polypeptide deformylases
    Jianzhong Huang
    Microbiology Department, GlaxoSmithKline, 1250 S Collegeville Road, Collegeville, PA 19426, USA
    J Bacteriol 188:5249-57. 2006
    ..pneumophila. These results indicate that even though L. pneumophila has three PDFs, they can be effectively inhibited by PDF inhibitors which can, therefore, have potent anti-L. pneumophila activity...
  4. pmc Selection of retapamulin, a novel pleuromutilin for topical use
    Stephen Rittenhouse
    Department of Microbiology Research, MMPD CEDD, GlaxoSmithKline Pharmaceuticals, 1250 S Collegeville Rd, Collegeville, PA 19426 0989, USA
    Antimicrob Agents Chemother 50:3882-5. 2006
    ..12 microg/ml and 0.016 microg/ml, respectively. Retapamulin has a low propensity to select resistance and produces an in vitro postantibiotic effect...
  5. pmc Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322
    Karen O'Dwyer
    Antibacterial Discovery Performance Unit, Infectious Disease Therapeutic Area, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Antimicrob Agents Chemother 57:2333-42. 2013
    ..Given the antibacterial potency demonstrated against this panel of organisms, GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens...
  6. pmc Staphylococcus aureus formyl-methionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity
    Thomas Lewandowski
    Antibacterial Discovery Performance Unit, Infectious Diseases Therapeutic Area, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Antimicrob Agents Chemother 57:2929-36. 2013
    ....
  7. pmc Characterization of Streptococcus pneumoniae TrmD, a tRNA methyltransferase essential for growth
    Karen O'Dwyer
    Microbial, Musculoskeletal and Proliferative Diseases CEDD, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    J Bacteriol 186:2346-54. 2004
    ..Other heterologous nonsubstrate tRNA species, like, tRNA (Thr)(GGT), tRNA(Phe), and tRNA (Ala)(TGC), bind the enzyme with similar affinities, suggesting that tRNA specificity is achieved via a postbinding event(s)...
  8. pmc Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae
    Pan F Chan
    Microbial, Musculoskeletal and Proliferative Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, USA
    J Bacteriol 185:2051-8. 2003
    ..The endogenous fuculose kinase promoter is a tightly regulated, titratable promoter which will be useful for target validation and for confirmation of the mode of action of novel antibacterial drugs in S. pneumoniae...
  9. ncbi request reprint Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin
    Glenn S Van Aller
    Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA
    Biochemistry 44:253-60. 2005
    ..T., et al. (2004) Bioorg. Chem. 32, 178-191]. This study substantially extends our understanding of PDF inhibition and may facilitate the development of novel antibiotics...
  10. doi request reprint Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitors
    Rachel Totoritis
    Department of Biological Reagents, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA
    Biochemistry 50:6642-54. 2011
    ..Both of these interactions between the inhibitor and enzyme were found to be necessary to observe time-dependent inhibition, as elimination of either leads to its loss...
  11. doi request reprint Potent Sub-MIC Effect of GSK1322322 and Other Peptide Deformylase Inhibitors on In Vitro Growth of Staphylococcus aureus
    Deborah Butler
    Antibacterial Discovery Performance Unit, Infectious Disease Therapeutic Area, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Antimicrob Agents Chemother 58:290-6. 2014
    ..These effects may impact the clinical efficacy of GSK1322322 in serious infections caused by multidrug-resistant S. aureus. ..
  12. doi request reprint A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential
    Daniel R Gentry
    Antibacterial Discovery Performance Unit, Infectious Diseases Center of Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, United States
    J Microbiol Methods 83:254-6. 2010
    ..In a screen of 372 compounds from a synthetic compound collection with anti-Escherichia coli activity due to unknown modes of action at least 17% demonstrated potent membrane activity, enabling rapid discrimination of nuisance compounds...
  13. pmc Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections
    Anthony E Choudhry
    Microbial, Musculoskeletal and Proliferative Diseases and Bioinformatics, GlaxoSmithKline Pharmaceuticals, Collegeville Pennsylvania 19426, USA
    Antimicrob Agents Chemother 47:2051-5. 2003
    ..Here we report the identification of the Staphylococcus aureus coaA gene and characterization of the enzyme. We have also identified a series of low-molecular-weight compounds which are effective inhibitors of S. aureus CoaA...
  14. ncbi request reprint Novel antibacterials: a genomics approach to drug discovery
    Pan F Chan
    Department of Microbiology Microbial, Musculoskeletal and Proliferative Diseases CEDD, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426 0989, USA
    Curr Drug Targets Infect Disord 2:291-308. 2002
    ..Genomics can also increase the chemical diversity against which the novel targets can be screened...
  15. ncbi request reprint Insights into catalysis by a knotted TrmD tRNA methyltransferase
    Patricia A Elkins
    GlaxoSmithKline, 709 Swedeland Road, UE0447, King of Prussia, PA 19406, USA
    J Mol Biol 333:931-49. 2003
    ..Mutational analyses demonstrate that the knot is important for AdoMet binding and catalytic activity, and that the C-terminal domain is not only required for tRNA binding but plays a functional role in catalytic activity...